Can neurologic manifestations of Hughes (antiphospholipid) syndrome be distinguished from multiple sclerosis? Analysis of 27 patients and review of the literature - PubMed (original) (raw)
Review
Can neurologic manifestations of Hughes (antiphospholipid) syndrome be distinguished from multiple sclerosis? Analysis of 27 patients and review of the literature
M J Cuadrado et al. Medicine (Baltimore). 2000 Jan.
Free article
Abstract
Hughes (antiphospholipid) syndrome (APS) can mimic multiple sclerosis (MS). We analyzed the clinical, laboratory, and imaging findings of MS-like expression in a cohort of patients with APS in an attempt to identify parameters that might differentiate the 2 entities. We studied 27 patients who were referred to our unit with the diagnosis of probable or definite MS made by a neurologist. All patients were referred to our lupus clinic because of symptoms suggesting an underlying connective tissue disease, uncommon findings for MS on magnetic resonance imaging (MRI), atypical evolution of MS, or antiphospholipid antibody (aPL) positivity. aPL, antinuclear antibody (ANA), anti-dsDNA, and anti-extractable nuclear antigen (ENA) antibodies were measured by standard methods. MRI was performed in every patient and compared with MRI of 25 definite MS patients who did not have aPL. An index severity score was calculated based on the size and number of increased signal intensity areas in MRI. In the past medical history, 8 patients with primary APS and 6 with APS secondary to systemic lupus erythematosus (SLE) had had symptoms related to these conditions. Neurologic symptoms and physical examination of the patients were not different from those common in MS patients. Laboratory findings were not a useful tool to distinguish APS from MS. When MRI from APS patients was compared globally with MRI from MS patients, MS patients had significantly increased severity score in white matter (p < 0.001), cerebellum (p = 0.035), pons (p < 0.015), and when all areas were taken together (p < 0.001). Patients with APS had significantly increased scores in the putamen (p < 0.01). No differences were noticed in the degree of atrophy. When taken individually, MRI from APS patients could not be distinguished from MRI from MS patients. Most of the patients with primary APS showed a good response to oral anticoagulant treatment. In patients with secondary APS, the outcome was poorer. Hughes syndrome (APS) and MS can be difficult to distinguish. A careful medical history, a previous history of thrombosis and/or fetal loss, an abnormal localization of the lesions in MRI, and the response to anticoagulant therapy might be helpful in the differential diagnosis. We believe that testing for aPL should become routine in all patients with MS.
Similar articles
- Hughes syndrome and multiple sclerosis.
Uthman I, Noureldine MH, Berjawi A, Skaf M, Haydar AA, Merashli M, Hughes GR. Uthman I, et al. Lupus. 2015 Feb;24(2):115-21. doi: 10.1177/0961203314555539. Epub 2014 Oct 17. Lupus. 2015. PMID: 25326228 Review. - Hughes syndrome and epilepsy: when to test for antiphospholipid antibodies?
Noureldine MH, Harifi G, Berjawi A, Haydar AA, Nader M, Elnawar R, Sweid A, Al Saleh J, Khamashta MA, Uthman I. Noureldine MH, et al. Lupus. 2016 Nov;25(13):1397-1411. doi: 10.1177/0961203316651747. Epub 2016 Jul 11. Lupus. 2016. PMID: 27225212 Review. - Multiple sclerosis, neuropsychiatric lupus and antiphospholipid syndrome: where do we stand?
Ferreira S, D'Cruz DP, Hughes GR. Ferreira S, et al. Rheumatology (Oxford). 2005 Apr;44(4):434-42. doi: 10.1093/rheumatology/keh532. Epub 2005 Jan 11. Rheumatology (Oxford). 2005. PMID: 15644391 Review. - Anti-phospholipid antibodies in patients with multiple sclerosis and MS-like illnesses: MS or APS?
IJdo JW, Conti-Kelly AM, Greco P, Abedi M, Amos M, Provenzale JM, Greco TP. IJdo JW, et al. Lupus. 1999;8(2):109-15. doi: 10.1191/096120399678847461. Lupus. 1999. PMID: 10192504 - The value of IgA antiphospholipid testing for diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus.
Bertolaccini ML, Atsumi T, Escudero Contreras A, Khamashta MA, Hughes GR. Bertolaccini ML, et al. J Rheumatol. 2001 Dec;28(12):2637-43. J Rheumatol. 2001. PMID: 11764209
Cited by
- Neuroimaging techniques in the diagnostic work-up of patients with the antiphospholipid syndrome.
Rovaris M, Pedroso C, Filippi M. Rovaris M, et al. Curr Rheumatol Rep. 2001 Aug;3(4):301-6. doi: 10.1007/s11926-001-0034-1. Curr Rheumatol Rep. 2001. PMID: 11470048 Review. - Antiphospholipid Syndrome and the Neurologist: From Pathogenesis to Therapy.
Fleetwood T, Cantello R, Comi C. Fleetwood T, et al. Front Neurol. 2018 Nov 26;9:1001. doi: 10.3389/fneur.2018.01001. eCollection 2018. Front Neurol. 2018. PMID: 30534110 Free PMC article. Review. - Involvement of tissue plasminogen activator in onset and effector phases of experimental allergic encephalomyelitis.
Lu W, Bhasin M, Tsirka SE. Lu W, et al. J Neurosci. 2002 Dec 15;22(24):10781-9. doi: 10.1523/JNEUROSCI.22-24-10781.2002. J Neurosci. 2002. PMID: 12486171 Free PMC article. - Evidence of platelet activation in multiple sclerosis.
Sheremata WA, Jy W, Horstman LL, Ahn YS, Alexander JS, Minagar A. Sheremata WA, et al. J Neuroinflammation. 2008 Jun 27;5:27. doi: 10.1186/1742-2094-5-27. J Neuroinflammation. 2008. PMID: 18588683 Free PMC article. - Nonpainful phantom sensation, illusory limb movement in a patient with dorsal myelitis. Neuropathological and SPECT findings.
de Andrés C, Gil R, López L, Salinero E, Bittini A. de Andrés C, et al. J Neurol. 2002 Jul;249(7):930-2. doi: 10.1007/s00415-002-0648-x. J Neurol. 2002. PMID: 12212555 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous